Immutep Ltd has released a press release.
Webcast slides for TACTI-mel clinical trial data
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Immutep
- Response to ASX Price Query
- Immutep raises A$6.85M through institutional placement
- US patent grant for IMP701 antibody
- Immutep receives A$686,704 R&D Tax Incentive
- Outcome of DSMB Safety Review & Extension of TACTI-mel
Later from Immutep
- Mid-point of patient enrolment reached in AIPAC trial
- Immutep submits IND application with FDA
- Immutep receives IND approval from US FDA for IMP321
- TACTI-mel Patient Recruitment Complete & Operational Update
- Appendix 4E & 2018 Full Year Statutory Accounts
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep